Jaguar Health reports Phase 3 OnTarget trial results for cancer supportive care drug Crofelemer on July 23rd.
Jaguar Health will report the Phase 3 OnTarget trial results for its cancer supportive care drug, Crofelemer, on July 23rd. The webcast will include updates on Jaguar's cancer supportive care portfolio and will feature participation from Jaguar's scientific team, patient advocates, and leading oncology experts in cancer therapy-related diarrhea (CTD) and oral mucositis. Crofelemer, the only oral prescription drug approved under FDA botanical guidance, is derived from the red bark sap of the Croton lechleri tree and is designed to prevent or substantially reduce diarrhea in adult cancer patients receiving targeted therapy with or without standard chemotherapy.
July 18, 2024
7 Articles